Form 4: Puma Biotech SVP Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, sold 8,987 shares of common stock in early January 2026 through a pre-arranged 10b5-1 trading plan.
Summary
- Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, Inc. (PBYI), reported sales of common stock.
- The transactions occurred on January 6, 2026, and January 7, 2026.
- On January 6, 2026, 3,973 shares were sold at a price of $5.844 per share.
- On January 7, 2026, 5,014 shares were sold at a price of $5.879 per share.
- These sales were conducted pursuant to a Rule 10b5-1(c) trading plan, which was adopted on December 14, 2020.
- Following these transactions, Douglas M. Hunt directly beneficially owns 155,907 shares of common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as this is a routine insider transaction under a pre-arranged 10b5-1 plan, which typically does not reflect new material information or a change in the insider's outlook on the company.
Future Outlook
NA
Industry Context
This is a routine insider transaction report and does not provide specific industry context or trends. Insider sales under 10b5-1 plans are common across industries for personal financial planning.
Stakeholder Impact
- Shareholders: Minimal impact as these are pre-scheduled sales under a 10b5-1 plan, indicating no new material information influencing the transactions.
Key Dates
| Date | Description |
|---|---|
| 12-14-2020 | Adoption date of the Rule 10b5-1(c) trading plan. |
| 01/06/2026 | Sale of 3,973 shares of common stock at $5.844 per share. |
| 01/07/2026 | Sale of 5,014 shares of common stock at $5.879 per share. |
| 01/08/2026 | Date the Form 4 was signed by Gordon Esplin as attorney-in-fact for Douglas M. Hunt. |
Recommendation
holdThe reported transactions are routine sales of common stock by an insider under a pre-arranged Rule 10b5-1 trading plan. Such sales are typically for personal financial planning and do not reflect a change in the insider's view of the company's prospects or new material non-public information. Therefore, this filing alone does not provide a basis to alter an existing investment thesis, warranting a 'hold' recommendation.
Keywords
PBYI, Puma Biotechnology, Douglas M. Hunt, insider trading, Form 4, stock sale, 10b5-1 plan, regulatory affairs, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.